Urologic Neoplasms
53
8
12
23
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.2%
7 terminated out of 53 trials
76.7%
-9.9% vs benchmark
6%
3 trials in Phase 3/4
30%
7 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 23 completed trials
Clinical Trials (53)
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Savolitinib vs. Sunitinib in MET-driven PRCC.
Spinal Versus General Anesthesia in Open Simple Prostatectomy
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
CD70-targeted immunoPET Imaging of Kidney Cancer
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer